News in NKF - Nanjing King-Friend

NKF's subsidiary Kindos’s self-developed Ropivacaine Hydrochloride Injection gets FDA approval for marketing

This once again fully demonstrates Kindos team the professional and efficient R&D capability, the international first-class cGMP manufacturing capability and the precise and rigorous pharmaceutical registration capability.

2024-08-07

Learn more +
Meitheal Pharmaceuticals Strengthens Biologics Portfolio with an Exclusive Commercial Licensing Agreement for YUSIMRY®, a Biosimilar of Humira®

Meitheal will work closely with Coherus to ensure a seamless transition of existing YUSIMRY® operations.

2024-06-27

Learn more +
Eptifibatide injection approved by USFDA，from Nanjing King-Friend subsidiary

May 9, 2024, Hong Kong King-Friend Industrial Company Limited. (hereinafter referred to as "HKF"), a subsidiary of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as "NKF"), received the approval letter from the US Food and Drug Administration (FDA) for Eptifibatide injection.

2024-05-20

Learn more +
Enoxaparin Sodium Injection of NKF approved in Egypt

March 28, 2024, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as "NKF) received the approval letter of Enoxaparin sodium injection fromEgyptian Drug Authority, the product officially launched in the market.

2024-05-14

Learn more +
Kindos’ (subsidiary of NKF) Bortezomib for injection getting approved by NMPA, submitted to NMPA and US FDA

April 30, 2024, Bortezomib for injection receives the approval letter by NMPA, formally approved for marketing in China, with independent research and development by Kindos Pharmaceuticals Co., Ltd (Hereinafter referred to ”Kindos”) .

2024-05-14

Learn more +
Good news! NKF and Livzon export Cetrorelix Acetate for Injection first time to US

On April 27, 2024, Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd (hereinafter referred to as "NKF") and Livzon Group export Cetrorelix Acetate for Injection to the United States for the first time.

2024-04-29

Learn more +
Kindos creates the new record for fastest approval by FDA: Dacarbazine for Injection

On April 3, 2024, Dacarbazine for Injection of Kindos Pharmaceuticals Co., Ltd.（Subsidiary of Nanjing Kingfriend） got approved for commercial sale by US FDA via conditional accelerated approval.

2024-04-16

Learn more +
【Explore the future of the pharmaceutical industry】 Kingfriend will meet you in CPHI Barcelona!

2023-10-17

Learn more +

Stock price

14.720

-0.91

©2024 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd苏ICP备13012010号